Results 121 to 130 of about 59,224 (329)

The Memory Effect on Fractional Calculus: An Application in the Spread of Covid-19 [PDF]

open access: yesComput Appl Math, 2021
de Barros LC   +5 more
europepmc   +2 more sources

On fractional Bullen-type inequalities with applications

open access: yesAIMS Mathematics
Integral inequalities in mathematical interpretations are a substantial and ongoing body of research. Because fractional calculus techniques are widely used in science, a lot of research has recently been done on them.
Sobia Rafeeq, Sabir Hussain, Jongsuk Ro
doaj   +1 more source

β‐TrCP overexpression enhances cisplatin sensitivity by depleting BRCA1

open access: yesMolecular Oncology, EarlyView.
Low levels of β‐TrCP (Panel A) allow the accumulation of BRCA1 and CtIP, which facilitate the repair of cisplatin‐induced DNA damage via homologous recombination (HR) and promote tumor cell survival. In contrast, high β‐TrCP expression (Panel B) leads to BRCA1 and CtIP degradation, impairing HR repair, resulting in persistent DNA damage and apoptosis ...
Rocío Jiménez‐Guerrero   +8 more
wiley   +1 more source

Semilocal convergence of Newton-like methods under general conditions with applications in fractional calculus

open access: yesJournal of Numerical Analysis and Approximation Theory, 2015
We present a semilocal convergence study of Newton-like methods on a generalized Banach space setting to approximate a locally unique zero of an operator.
George A. Anastassiou   +1 more
doaj   +2 more sources

Fractional Calculus of Analytic Functions Concerned with Möbius Transformations

open access: yesJournal of Function Spaces, 2016
Let A be the class of functions f(z) in the open unit disk U with f(0)=0 and f′(0)=1. Also, let w(ζ) be a Möbius transformation in U for some z∈U.
Nicoleta Breaz   +2 more
doaj   +1 more source

Olaparib synergy screen reveals Exemestane induces replication stress in triple‐negative breast cancer

open access: yesMolecular Oncology, EarlyView.
Screening 166 FDA‐approved anticancer drugs identifies the aromatase inhibitor Exemestane as a synergistic partner of PARP inhibitor Olaparib in BRCA‐proficient triple‐negative breast cancer. Exemestane induces ROS‐mediated replication stress, enhancing DNA damage and apoptosis alongside Olaparib.
Nur Aininie Yusoh   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy